Available technologies
Hematopoietic prostaglandin D2 synthase (HPGD2S) inhibitors for inflammatory disease including DMD and asthma
Team
Life Science
Industry
Healthcare
Sector
Therapeutic Programs
Small molecule inhibitors of hematopoietic prostaglandin D2 synthase (HPGD2S) for inflammatory disease including DMD and asthma.
Key features
- Potent, selective and orally administrable small molecule compounds.
- Down-regulates multiple clinically validated targets.
- Selective expression resulting in improved safety – HPGD2S is primarily expressed peripheral tissues (mast and Th2 cells).
- First in class opportunity for the treatment of asthma and allergic rhinitis.
